Economical effect of lumen apposing metal stents for treating benign foregut strictures. by Hallac, Alexander et al.
Providence St. Joseph Health
Providence St. Joseph Health Digital Commons
Journal Articles and Abstracts
10-16-2018
Economical effect of lumen apposing metal stents
for treating benign foregut strictures.
Alexander Hallac
Providence Gastroenterology, Spokane, WA 99204, United States.
Wichit Srikureja
Providence Gastroenterology, Spokane, WA 99204, United States.
Eashen Liu
Providence Gastroenterology, Spokane, WA 99204, United States.
Parag Dhumal
Ashish Thatte
See next page for additional authors
Follow this and additional works at: https://digitalcommons.psjhealth.org/publications
Part of the Gastroenterology Commons
This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has been accepted for inclusion in Journal
Articles and Abstracts by an authorized administrator of Providence St. Joseph Health Digital Commons. For more information, please contact
digitalcommons@providence.org.
Recommended Citation
Hallac, Alexander; Srikureja, Wichit; Liu, Eashen; Dhumal, Parag; Thatte, Ashish; and Puri, Nishant, "Economical effect of lumen
apposing metal stents for treating benign foregut strictures." (2018). Journal Articles and Abstracts. 779.
https://digitalcommons.psjhealth.org/publications/779
Authors
Alexander Hallac, Wichit Srikureja, Eashen Liu, Parag Dhumal, Ashish Thatte, and Nishant Puri
This article is available at Providence St. Joseph Health Digital Commons: https://digitalcommons.psjhealth.org/publications/779
Alexander Hallac, Wichit Srikureja, Eashen Liu, Parag Dhumal, Ashish Thatte, Nishant Puri
ORIGINAL ARTICLE
294 October 16, 2018|Volume 10|Issue 10|WJGE|www.wjgnet.com
Economical effect of lumen apposing metal stents for 
treating benign foregut strictures
Alexander Hallac, Wichit Srikureja, Eashen Liu, Nishant 
Puri, Providence Gastroenterology, Spokane, Wa 99204, United 
States
Parag Dhumal, College of Business, Economics and Computing,
University of Wisconsin-Parkside, Kenosha, WI 53144, United 
States
Ashish Thatte, School of Business administration, Gonzaga 
University, Spokane, Wa 99258, United States
ORCID number: alexander Hallac (0000-0003-1347-3766); 
Eashen Liu (0000-0002-0609-8112); Wichit Srikureja (0000 
-0002-6559-3930); Parag Dhumal (0000-0002-7040-9499); 
ashish Thatte (0000-0002-9319-4363); Nishant Puri (0000 
-0003-2420-3809)
Author contributions: Hallac a and Srikureja W designed 
research; Liu E, Dhumal P, Thatte a and Puri N performed 
research and contributed new reagents/analytic tools; all authors 
analyzed data and wrote the paper.
Institutional review board statement: Providence Health Care 
(Spokane) approves this study, and is part of the corresponding 
author home institution.
Conflict-of-interest statement: all authors have no conflicts of 
interest to report.
STROBE statement: The STROBE Statement has been adopted.
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Manuscript source: Unsolicited Manuscript
Correspondence to: Nishant Puri, MD, FACP, FACG, 
Providence Gastroenterology, 105 W. 8th avenue, Suite 7050, 
Submit a Manuscript: http://www.f6publishing.com
DOI: 10.4253/wjge.v10.i10.294
World J Gastrointest Endosc  2018 October 16; 10(10): 294-300
ISSN 1948-5190 (online)
Spokane, Wa 99204, United States. npurigi@gmail.com
Telephone: +1-509-2521711
Fax: +1-509-2277070
Received: June 29, 2018 
Peer-review started: June 30, 2018
First decision: July 19, 2018
Revised: July 27, 2018
Accepted: august 21, 2018
Article in press: august 21, 2018
Published online: October 16, 2018
Abstract
AIM
To evaluate the clinical and economical efficacy of lumen 
apposing metal stent (LAMS) in the treatment of benign 
foregut strictures.
METHODS
A single center retrospective database of patients who 
underwent endoscopic treatment of benign foregut 
strictures between January 2014 and May 2017 was 
analyzed. A control group of non-stented patients who 
underwent three endoscopic dilations was compared 
to patients who underwent LAMS placement. Statistical 
tests performed included independent t -tests and five-
parameter regression analysis
RESULTS
Nine hundred and ninety-eight foregut endoscopic 
dilations were performed between January 2014 and 
May 2017. 15 patients underwent endoscopic LAMS 
placement for treatment of benign foregut stricture. 
Thirty-six patients with recurrent benign foregut stri-
ctures underwent three or more endoscopic dilations 
without stent placement. The cost ratio of endoscopic 
dilation to LAMS (stent, placement and retrieval) is 
5.77. Cost effective analysis demonstrated LAMS to 
be economical after three endoscopic dilation overall. 
Case Control Study
LAMS was cost effective after two dilations in the Post-
surgical stricture subgroup. 
CONCLUSION
Endoscopists should consider LAMS for the treatment of 
benign foregut strictures if symptoms persist past three 
endoscopic dilations. Post-surgical strictures may benefit 
from LAMS if symptoms persist after two dilations in a 
post-surgical. Early intervention with LAMS appears to 
be a clinically and economically viable option for durable 
symptomatic relief in patients with these strictures.
Key words: Benign esophageal stricture; Endoscopy 
economics; Stent economics; Self expandable metallic 
stents; Esophageal diseases
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The findings of our study will be helpful with 
clinical decision making when treating benign strictures 
of the esophagus and foregut. The main finding of 
our study is that lumen apposing metal stents have 
the potential to have an economical advantage over 
repeated dilations in the treatment of recurrent benign 
foregut strictures. Reports of placing lumen apposing 
stents as an alternative to serial endoscopic dilation 
have been reported, however no economic analysis has 
been published.
Hallac a, Srikureja W, Liu E, Dhumal P, Thatte a, Puri N. 
Economical effect of lumen apposing metal stents for treating 
benign foregut strictures. World J Gastrointest Endosc 2018; 
10(10): 294-300  available from: URL: http://www.wjgnet.
com/1948-5190/full/v10/i10/294.htm  DOI: http://dx.doi.
org/10.4253/wjge.v10.i10.294
INTRODUCTION
Pathological or therapeutic disruption of the foregut 
tissue is common, yet diverse in both its etiology and 
severity. Surgical anastomosis, peptic injury, radiation, 
caustic ingestion, eosinophilic esophagitis, Schatzki 
rings and esophageal webs all disrupt the innate tissue 
and predispose to luminal stricture formation[1,2]. The 
mechanism by which esophageal strictures develop is 
hypothesized to be the result of fibrous tissue production 
and collagen deposition stimulated by deep ulceration 
or chronic inflammation[3,4]. The principle symptoms of 
foregut stricture disease include, dysphagia, early satiety, 
epigastric pain, heart burn, nausea and vomiting. The 
current gold standard treatment of foregut strictures is 
endoscopic dilation. It is not uncommon for patients to 
undergo multiple dilations to achieve remission, while 
some have persistent disease forcing clinicians to face 
challenging management decisions. Currently, there 
are no established reliable predictors to identify which 
strictures will respond optimally to dilation. Additionally, 
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there is no expert consensus regarding the frequency of 
dilations necessary to define a refractory structure[5]. 
An evolving, but “off label” treatment for benign 
foregut strictures is placing stents for sustained eso­
phageal patency. The use of self­expandable metal stents 
(SEMS) has the benefit of providing an ongoing radial 
force to suppress the stricture and maintain luminal 
patency. The SEMS design has been innovated upon, 
ultimately resulting in the creation of the lumen apposing 
metal stent (LAMS). LAMS are short, self­expanding, 
fully covered, metal stents with large flanges that 
anchor the stent at both ends.
Clinical guidelines, supported by large studies and 
systemic reviews have validated the use of stents as an 
acceptable salvage therapy in the treatment of refractory 
benign and malignant strictures; however, these studies 
did not include LAMS[5­10]. 
The objective of this study is to examine the use of 
LAMS in the treatment of benign foregut strictures. Case 
series and case reports have documented the use of 
LAMS in benign strictures of various etiology at different 
locations in the foregut[11­17]. We aim to illustrate the 
clinical effectiveness and economics of LAMS. 
MATERIALS AND METHODS
Institutional review board approval was obtained for the 
development of a retrospective database to evaluate 
the efficacy of LAMS in the treatment of benign foregut 
strictures. The database used for this study included all 
patients who underwent endoscopic dilation or LAMS 
placement for treatment of benign foregut strictures at 
a single non­university tertiary care center. The database 
was constructed by manual review of the electronic 
health record (EHR) system of a large regional health 
system. This retrospective case­control study was re­
ported in accordance with the STROBE statement[18]. 
Current procedural terminology (CPT) codes were 
used to identify the most recent 1000 controlled radial 
balloon dilation (CRE) and Savary­Gilliard dilations 
of the foregut. All endoscopic procedures performed 
between January 2014 and May 2017 was reviewed, 
998 procedures were identified. These procedures 
were reviewed to isolate all patients who underwent 
three or more CRE or Savary­Gilliard dilations during the 
40­mo period, and 36 patients fit these criteria. Three 
or more dilations were selected as our inclusion criteria 
for recurrent strictures based on the fact that LAMS 
placement required a minimum of two endoscopies 
and LAMS placement is rarely first line therapy at our 
institution. The 36 patients’ medical records were inter­
rogated to establish a control group for the comparison 
of LAMS versus serial endoscopic dilation. 
Fifteen patients underwent endoscopic LAMS place­
ment for treatment of benign foregut stricture disease. 
The LAMS were placed without electrocautery or sutures 
with the intention of maintaining luminal patency for 90 
d or until surgical revision. The LAMS utilized were 10 
mm in length, fully covered, with bilateral 21 mm or 24 
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Table 1  The mean time between dilations for all patients in the recurrent dilation group
mm flanges. When deployed the stent self­expanded 
to a luminal diameter of 10 mm or 15 mm (Axios™ 
Stent, Boston Scientific©, Marlborough, MA, United 
States). The patients who underwent LAMS placement 
consented to undergoing treatment with a medical 
device in an “off label” non­United States Federal Drug 
Enforcement Agency (FDA) approved indication. 
Clinical end points were the number of symptom 
free days and the number of days between endoscopic 
dilations. The number of symptom free days and days 
between each endoscopic procedure was determined by 
documentation in the EHR and reported as mean time 
between dilations (MTBD) and mean symptom free 
days (MSFD). The review of EHR documentations was 
performed by a physician who is not a gastroenterologist 
to prevent potential bias. Complications were defined as 
removal of the stent prior to the intended 90­d duration 
of placement or hospital admission for gastrointestinal 
symptoms. Endoscopies performed prior to this study’s 
2014 start date were reviewed when available. 
Statistical analysis
All statistical analysis was performed by a biostastician 
using IBM SPSS Statistics for Windows, Version 24 
(IBM Corp., Armonk, NY, United States). Statistical 
tests performed included independent t-tests and five-
parameter regression analysis with the independent 
variable being endoscopic dilations as pair indices and 
the dependent variable being time. All patients that 
lacked sufficient follow up to accurately characterize 
their post stent clinical course were included in the 
descriptive statistical analysis and excluded from 
the case control analysis. Statistical significance was 
determined using a threshold of P = 0.05.
Economic analysis
The economic analysis was designed utilizing the 
recommendations of the International Association of 
Health Technology Agencies to increase generalizability 
to clinical gastroenterologists[19]. The 2016 Medicare 
National Average Payment fee schedule that was issued 
by Center for Medicare and Medicaid Services in January 
of 2016 was used to determine the cost of endoscopic 
interventions. A 2% reduction was calculated on all 
costs to reflect the sequestrations placed by the United 
States government on all Medicare rates. The cost we 
associated with each endoscopic dilation is the mean 
cost of a CRE and Savary­Gilliard dilations. The cost of 
the LAMS was the specific per unit cost at our institution. 
The breakeven number for using a stent is calculated by 
dividing the delta between the MSFD and MTBD by the 
coefficient of the regression.
RESULTS 
Recurrent dilation group
Strictures of non­anastomotic origin accounted for 
86.1% (n = 31). Five post­surgical strictures located at 
anastomotic sites accounted for 13.9% of the recurrent 
dilation group (Table 1). Patients’ ages ranged from 
26 to 90 years with a median of 66 years of age. The 
majority of patients were men (55.6%, n = 20). The 
MTBD was 147 ± 156 d. 
The regression results demonstrate that after the 
initial endoscopic dilation, patients with recurrent 
benign esophageal strictures will have a decreased time 
between subsequent dilations that averages 28 d. The 
reduction of time between subsequent dilations was 20 
d in non­surgical strictures and 64 d in postoperative 
strictures.
LAMS group
The LAMS group consisted of 15 patients who underwent 
endoscopic LAMS placement as an adjunctive treatment 
for various benign strictures of the foregut (Table 2). 
Strictures occurred post surgically at locations including: 
Gastrojejunal anastomosis (GJ), Roux­en­Y gastric 
bypass (RYGB), vertical band gastroplasty (VBG), 
esophagogastric anastomosis (EG). The majority of 
the LAMS group were post­surgical strictures, of which 
27% (n = 4) resulted from weight loss surgeries. 
Thirteen percent (n = 2) of patients had post procedural 
dysphagia and abdominal pain leading to elective 
premature LAMS removal (Table 2). Patient eight 
obtained partial relief of dysphagia on the initial LAMS 
which recurred promptly after LAMS removal prompting 
insertion of a second LAMS 21 d later intended to 
provide symptomatic relief prior to surgical intervention. 
Patient 14 underwent LAMS placement for a persistent 
peptic stricture of the duodenal bulb which initially 
relieved some symptoms, however; symptoms recurred 
and the LAMS was removed and replaced 74 d later for 
worsening symptoms.
The median length of follow up was 299 d (range, 
7­628). The median duration of the endoscopic LAMS 
placement was 14.7 min (range, 3.3­68.3), LAMS 
removal had a median endoscopy duration of 14.7 min 
(range, 1.7­28.2).
Sixty percent (n = 8) of the LAMS group had suffi-
cient follow up for inclusion in a multivariate regression 
n Mean time between dilations (d) SD t  P
Male 20 146.8 169.7   -0.01 0.9
Female 16 147.5 141.1
Non-Surgical 31 137.6 159.9 -1.1 0.3
Surgical   5 205.7 121.4
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Table 5  The economic analysis for lumen apposing metal stent utilization
Economic analysis results
The average cost of an endoscopic dilation is $1282, 
whereas the cost of a LAMS is $4060, endoscopic in­
sertion and endoscopic removal cost $2399 and $937 
respectively. The total cost for the LAMS and endoscopic 
insertion and removal is $7396; thus, a cost ratio is 5.7. 
Dividing the overall MSFD for the LAMS group and the 
recurrent dilation group by the cost ratio demonstrates 
that LAMS placement only became economical when the 
time between dilation is less than or equal to 57 d (Table 
5). The overall MTBD for the recurrent dilation and LAMS 
group is 152 d. The overall breakeven number for using 
LAMS is 3.5 dilations, thus endoscopic LAMS placement 
is economical after the three dilations. 
DISCUSSION
The use of esophageal prosthesis began over a century 
ago and progressed into commercially available app­
lications in the 1970s. The current generation of SEMS 
were initially used in the biliary tree before being 
developed into esophageal specific applications in the 
1990’s[20]. The recommended use of SEMS is most 
clearly defined in the malignant stricture population; 
however, ambiguity exists in the use of SEMS in benign 
strictures of the gastrointestinal tract. Complications of 
stent migration and variability in efficacy of SEMS have 
limited their use in benign strictures. 
The FDA approved the first LAMS in 2012 for the 
endoscopic treatment of pancreatic pseudocysts[21]. 
There is a paucity of published experience using LAMS 
in the treatment of benign foregut strictures, with only 
three studies, including ours, containing 15 or more 
patients[11,12]. The limited number of studies utilizing 
LAMS in benign stricture disease is primarily due to the 
low use of “off label” non­FDA approved devices. As such, 
we believe our results along with Irani et al[12] and Yang 
et al[11]’s showcase the utility of LAMS in the treatment of 
benign foregut strictures. 
Clinical outcomes 
Our results are most similar to the prospective multi­
center trial performed by Yang et al[11]. Yang et al[11]’s 
cohort included 23 patients who underwent an average 
of 3.7 endoscopic dilations prior to LAMS placement. 
As such, this demonstrated the generalizability of our 
control group, which included individuals who underwent 
three or more endoscopic dilations. In addition to the 23 
foregut LAMS placements, Yang et al[11]’s cohort included 
four colonic stricture stent placements with 60 d (IQR, 
40­90 d) median duration of LAMS placement compared 
to our median of 96 d (IQR, 41­161 d). Both our cohort 
Table 3  Regression analysis of the time between dilation (d) for patients who underwent lumen apposing metal stent placement
R2 Intercept Coefficient F P
Mean overall 68.3% 220.3 -27.8 8.6 0.04
Mean female 16.9% 192 -17.4 0.8 0.41
Mean male 96.1% 250 -39.3                99.3   0.001
Mean surgical 62.2%   96.2 -63.3 6.5 0.06
Mean nonsurgical 62.8% 188.3 -19.4 6.7 0.06
Table 4  The comparison of clinical outcomes in the lumen apposing metal stent and recurrent dilation groups
Group n Mean symptom free days SD t  P  (two tail)
Overall Dilation 36 153 153.7 2.9 0.01
LAMS   8 327 156.9
Male Dilation 20 147   169.04 3.5 0.01
LAMS   3 347   73.7
Female Dilation 16 160 137.2 2.1 0.09
LAMS   5 353 190.9
Nonsurgical Dilation 31 144 158.7 1.5 0.26
LAMS   3 298 165.6
Surgical Dilation   5 209   114.08   2.06 0.07
LAMS   5 382 148.8
LAMS: Lumen apposing metal stent.
MSFD MSFD/Cost Ratio MTBD Coefficient from Regression Breakeven n
Overall 327 56.7 153 27.8 3.4
Male 347 60.1 147 39.3 2.2
Surgical 382 66.2 209 63.3 2.2
MSFD: Mean symptom free days; MTBD: Mean time between dilations (d). 
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and Yang et al[11]’s did not experience any tissue over­
growth or technical difficulties with LAMS removal; yet, 
these issues were encountered in Irani et al[12]’s series. 
The adverse events related to LAMS extraction could 
be more prevalent in Irani et al[12]’s series due to their 
300 d median follow up time post LAMS insertion, which 
is slightly larger than both Yang et al[11]’s and our own 
cohort, which had median follow up times of 100 and 
299 d respectively. Yang et al[11], Irani et al[12] and our 
own cohort all reported encountering patients with pain 
following LAMS insertion that was severe enough to 
prompt premature LAMS removal, the mean incidence 
of premature LAMS removal due to pain was 6% 
(range, 4.3%­7%). Our study included a unique adverse 
event after LAMS was placed across a duodenal bulb 
stricture (Table 2, Patient 15), in which the distal flange 
of the stent created backpressure on the intraduodenal 
segment of the common bile duct leading to abdominal 
pain and obstructive jaundice resulting in stent removal 
20 d after placement.
Stent migration
In 2015, Fuccio et al[9] performed a meta­analysis of 
SEMS use in refractory benign esophageal stricture. 
Fuccio et al[9]’s meta­analysis reported a stent migration 
rate of 36% in fully covered self­expanding metal stents 
(FCSEMS)[9]. Twenty­two percent of the patients in Fuccio 
et al[9]’s analysis who underwent FCSEMS placement 
met the Kochman et al[22]’s criteria for refractory benign 
esophageal stricture meaning they underwent at least 
five dilation sessions and/or cycles with dilation to at 
least 14 mm. 
LAMS migration was confirmed in one of 15 patients 
in this study although a second stent migration could 
have occurred in the single patient lost to follow up 
(Table 2, Patient 11). Our reported LAMS migration rate 
of 6.7%­13.3% of patients is consistent with the two 
largest studies of LAMS that collectively had a migration 
rate of 7.5% in their 58 cases[12,13]. 
Clinical success 
Eighty­one percent of patients in our study had symp­
tomatic relief. Repeat endoscopic procedures after LAMS 
placement was limited to stent exchanges in two patients 
and a non­therapeutic endoscopy in one patient. LAMS 
successfully controlled symptoms in two patients prior 
to undergoing revision gastric surgery. Approximately 
83% of patients were symptom free at 100 d after LAMS 
removal in Yang et al[11]’s study, and the clinical success 
rate at 6 mo follow up was 61% in Irani et al[12]’s study. 
Economic analysis 
The cost breakeven point of the overall group is 3.5 and 
2.2 dilations in the post­surgical group, which shows that 
stent placement may have an economical advantage 
over recurrent dilation after the third dilation. The male 
subgroup demonstrated a cost breakeven point after 
the second dilation; however, this finding is limited by 
a lack of sufficient number of subjects to provide a fe-
male subgroup analysis. Although our study did not 
utilize Kochman et al[22]’s criteria for refractory benign 
esophageal strictures as an inclusion requirement, 
applying our breakeven point for LAMS placement would 
demonstrate LAMS to be cost effective in all benign 
recurrent esophageal strictures as defined by Kochman 
et al[22]. 
Endoscopists should welcome LAMS as a second line 
therapy for benign foregut strictures, as it has shown 
to be a clinically and economically effective treatment 
modality for managing the devastating symptoms of 
benign foregut strictures. 
An interesting secondary finding from the analysis 
of the control group was the time between dilations was 
decreasing by 28 d between each dilation. This surprising 
finding should be expanded on in further studies that aim 
to elucidate the pathogenesis of benign foregut stricture 
formation.
The most significant limitation of our study beyond 
those inherent to retrospective analysis is the low sample 
size; however, this is to be expected in the study of a 
non­FDA approved use of a medical device. The absence 
of a formal symptom scoring system at post procedure 
clinic visits and the inability to follow all subjects long 
term makes our data mildly vulnerable to subject re­
porting and selection bias. More prospective trials are 
needed to develop a professional consensus on the role 
of LAMS in the treatment of benign foregut strictures.
ARTICLE HIGHLIGHTS
Research background
The use of lumen apposing metal stents (LAMS) began in 2012 as a treatment 
modality for pancreatic pseudocysts. Currently, LAMS are being used in various 
endoscopic procedures such as pancreatic pseudocyst drainage. 
Research motivation
The key question of our study is How effective and economical is the use of 
LAMS in the treatment of benign foregut strictures. 
Research objectives 
The main objective of this study was to determine how to appropriately utilize 
LAMS in the treatment of benign foregut strictures. Benign foregut strictures 
frequently recur therefore this study will contribute to the literature used to 
determine treatment strategies for these difficult recurrent strictures. 
Research methods
The research methods that were adopted to realize our objective was a 
single center retrospective case-control study. The case-control study was 
complemented by a cost effectiveness analysis. 
Research results
The cost breakeven point of using a LAMS compared to repeat endoscopic 
dilation was 3.5 and 2.2 dilations in patients with benign foregut strictures 
and post-surgical strictures, respectively. Our results demonstrate that stent 
placement may have an economical advantage over recurrent dilation once a 
patient has undergone three endoscopic dilations. The optimal duration of stent 
placement to provide maximum efficacy and minimum adverse events remains 
unknown, further prospective multicenter studies are needed.
Research conclusions
This study presents the novel finding that inserting a LAMS instead of serial 
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dilations can be a cost-effective treatment. We believe our results demonstrate 
that recurrent endoscopic dilation of benign foregut strictures can be optimally 
treated by LAMS in well selected patients. In summary, this study demonstrates 
that the interval between endoscopic dilations decreases overtime after each 
subsequent dilation. The use of LAMS for benign foregut strictures has been 
reported however we utilized an economic analysis to prove our hypothesis that 
there is a potential cost savings. 
Research perspectives
This study has important clinical implications particularly in the United States 
where the placement of a LAMS for any reason other than evacuating a 
pancreatic pseudocyst is not Federal Drug Enforcement Agency approved. 
Endoscopists can incorporate the findings of this study into their clinical practice 
when treating patients whose benign foregut strictures continue to require 
endoscopic dilations. 
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